RxDoctor Payments Data

Jyoti Mohanty, MD

Interventional Cardiology · West Palm Beach, FLNPI 1841245917

Payments from drug & device makers

$143,416in general payments, 2019–2025

Across 1,047 payments — averaging $136.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$55K
  • E.r. Squibb & Sons, L.L.C.$24K
  • Cardiva Medical, Inc.$20K
  • Novartis$10K
  • Medtronic$7K
  • Esperion Therapeutics, Inc.$7K
  • plus $20K from 44 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$109,89077%
  • Travel & lodging$1,5731%
  • Food & beverage$31,60822%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,416 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$2,389,641
Medicare patients
2,269
Services billed
16,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,176$1,243,928
XareltoRivaroxaban350$383,014
EntrestoSacubitril/Valsartan197$251,122
JardianceEmpagliflozin128$156,315
Repatha SureclickEvolocumab166$142,325
CorlanorIvabradine Hcl36$35,670
BrilintaTicagrelor45$27,512
MultaqDronedarone Hcl12$27,453
Praluent PenAlirocumab35$18,064
Ranolazine ErRanolazine198$17,450
Repatha PushtronexEvolocumab16$13,705
Metoprolol Succinate864$12,904
EdarbiAzilsartan Medoxomil20$12,148
Sildenafil Citrate60$10,774
Midodrine Hcl115$10,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$432$1,243,9281,176 claims
Johnson & JohnsonXarelto$55,076$383,014350 claims
NovartisEntresto$9,919$251,122197 claims
Boehringer IngelheimJardiance$1,510$156,315128 claims
AmgenCorlanor$986$35,67036 claims
AstraZenecaBrilinta, Symbicort$232$32,12163 claims
Sanofi-aventis U.S. LLCMultaq$195$27,45312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →